Piggyback CAR ride

The disappointing durability of CAR T cells in the clinic has been attributed to the cells’ too-mature phenotype, and the immunogenicity and low stability of the chimeric antigen receptors (CARs) themselves. Poseida Therapeutics Inc. is using its virus-free gene delivery technology to load up T cells with modifications that address all three problems and provide long-lasting responses.

The company is pursuing allogeneic and autologous CAR T therapies, in addition to NK cell therapies...